Welcome to our dedicated page for DOCUSIGN SEC filings (Ticker: DOCU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on DOCUSIGN's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into DOCUSIGN's regulatory disclosures and financial reporting.
DOCUSIGN, INC. (DOCU) insider sale notice under Rule 144. The filer reports an intended sale of 1,682 restricted common shares, valued at $135,064.60, through Morgan Stanley Smith Barney on 09/15/2025 on NASDAQ. The shares were acquired as restricted stock from the issuer on 08/10/2024. The filing also discloses two recent sales by the same person: 983 shares sold on 09/11/2025 for $78,040.37 and a larger sale of 22,875 shares on 06/18/2025 for $1,710,777.77. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Robert Chatwani, President General Manager, Growth at DocuSign, Inc. (DOCU), reported a sale of company stock on 09/11/2025. The Form 4 shows a disposition of 983 shares at a price of $79.39 per share, leaving 71,143 shares beneficially owned in a direct form. The filing indicates the transaction was executed pursuant to a Rule 10b5-1 trading plan, and the form was signed by an attorney-in-fact.
Teresa Briggs, a director of DocuSign, Inc. (DOCU), reported a sale of common stock under a pre-established plan. On 09/11/2025 she disposed of 364 shares at a price of $79.39 per share. Following the reported transaction she beneficially owned 9,170 shares, held directly. The filing indicates the sale was effected pursuant to a Rule 10b5-1 trading plan and the Form 4 was signed by an attorney-in-fact on her behalf.
Form 144 for DOCU reports a proposed sale of 983 common shares through Morgan Stanley Smith Barney with an aggregate market value of $78,040.37, slated for approximately 09/11/2025 on NASDAQ. The shares were acquired as performance shares from the issuer on 09/10/2024. The filing also discloses a prior sale by an insider, Robert Chatwani, of 22,875 shares on 06/18/2025 for $1,710,777.77. The notice includes the standard certification that the seller is not aware of undisclosed material adverse information at the time of signing.
Form 144 notice for DocuSign, Inc. (DOCU) documents a proposed sale of 364 common shares, with an aggregate market value of $28,897.96, to be executed on 09/11/2025 on NASDAQ through Morgan Stanley Smith Barney LLC, Executive Financial Services. The shares were acquired as restricted stock from the issuer on 05/29/2025 and payment is recorded on that same date. The filing lists total outstanding shares of 201,104,117. The notice includes a representation that the seller does not possess undisclosed material information and references prior sales of 534 shares on 06/16/2025 with gross proceeds of $39,713.58.
Michael G. Rosenbaum, a director of DocuSign, Inc. (DOCU), was granted 6,265 restricted stock units (RSUs) on 09/09/2025. Each RSU converts to one share of common stock upon vesting and was issued at no cash price. The RSUs vest in twelve equal quarterly installments over three years, with a vesting commencement date of 09/03/2025, provided the reporting person remains a service provider through each vesting date. The RSUs do not expire; they either vest or are canceled prior to vesting. The Form 4 was signed by an attorney-in-fact on 09/10/2025.
Initial Form 3 for DocuSign, Inc. (DOCU) reports that Michael George Rosenbaum filed as a director with an event date of 09/03/2025. The filing states no securities are beneficially owned by the reporting person at the time of the statement. The form was signed by an attorney-in-fact on 09/10/2025.
DocuSign reported interim results for the quarter ended July 31, 2025, emphasizing subscription-driven revenue and continued investment in its platform. Subscriptions represented approximately 98% of revenue for the three and six months ended July 31, 2025, and the company reported $2.3 billion of transaction price allocated to remaining performance obligations, with 57% expected to be recognized within 12 months. DocuSign serves over 1.7 million customers and more than a billion users worldwide. Contract assets were $9.9 million as of July 31, 2025. Information technology costs rose, increasing $7.7 million in the three-month period and $14.5 million for the six months ended July 31, 2025, reflecting cloud migration. The company repurchased 4.9 million shares for $384.9 million during the six months and has $1.2 billion of remaining repurchase authorization. DocuSign had a credit facility of $750 million with a $250 million accordion maturing in May 2030 and reported no outstanding borrowings under it as of July 31, 2025. The filing discloses ongoing securities and derivative litigation related to prior-period statements and continued valuation allowances for certain deferred tax assets.
DocuSign director Anna Marrs received 725 restricted stock units (RSUs) on 09/04/2025, reported on a Form 4. After the grant, she beneficially owns 11,527 shares of DocuSign common stock. The RSUs carry a $0 purchase price and represent contingent rights to one share each. They vest in twelve equal quarterly installments over three years beginning June 4, 2023, conditioned on continued service, and do not expire prior to vesting.
DocuSign, Inc. reported results for the three and six months ended July 31, 2025 via a press release furnished as Exhibit 99.1 to this Current Report. The Company announced the appointment of Mike Rosenbaum to the Board effective September 3, 2025 as a Class III director whose term expires at the Company’s 2027 Annual Meeting of Stockholders. The Board determined Mr. Rosenbaum is an independent director, there are no arrangements or related‑party interests requiring disclosure, and he will receive compensation under the Company’s existing Amended and Restated Director Compensation Program. Mr. Rosenbaum has also entered the Company’s standard indemnity agreement. The press release also announces James Beer as Board Chair; these disclosures are furnished under Regulation FD and are not "filed" for Section 18 liability.